WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the quarter ended September 30, 2006 and commented on operational progress. The Company indicated that its primary focus during the three months ended September 30, 2006 was on positioning the Imagify™ RAMP-2 trial for success by training the RAMP-2 echo blinded readers with recently unblinded RAMP-1 images. Imagify is an ultrasound contrast agent designed to screen for coronary heart disease, the leading cause of death in the U.S. Imagify-enhanced ultrasound is being evaluated in two Phase 3 clinical trials, RAMP-1 and RAMP-2, designed to demonstrate non-inferiority to nuclear stress tests, the leading imaging technique used to screen for coronary heart disease.
